These discrepant findings in the literature can be attributed to the extent of intestinal inflammation present when anti-TNF-α treatment was started, as when anti-TNF-α administration was done together with the adoptive transfer of colitogenic T cells (preventive treatment), Rag-/- H+ receptor mice were fully protected from colitis. The gene discussed is TNF; the disease is colitis.